Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Depatuxizumab mafodotin |
Synonyms | |
Therapy Description |
Depatuxizumab mafodotin (ABT-414) is an antibody-drug conjugate comprising an EGFR-targeted antibody linked to an anti-microtubule drug, which delivers the cytotoxic agent to EGFR-expressing cells, potentially resulting in increased tumor cell death and decreased growth of EGFR-overexpressing tumors (PMID: 26846818, PMID: 29075855, PMID: 31747009, PMID: 32371586). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Depatuxizumab mafodotin | ABT-414|depatux-m | EGFR Antibody 60 | Depatuxizumab mafodotin (ABT-414) is an antibody-drug conjugate comprising an EGFR-targeted antibody linked to an anti-microtubule drug, which delivers the cytotoxic agent to EGFR-expressing cells, potentially resulting in increased tumor cell death and decreased growth of EGFR-overexpressing tumors (PMID: 26846818, PMID: 29075855, PMID: 31747009, PMID: 32371586). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02343406 | Phase II | Lomustine Depatuxizumab mafodotin Temozolomide | ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma | Completed | USA | POL | NLD | ITA | IRL | HUN | GBR | FRA | FIN | ESP | DEU | CZE | CHE | CAN | BEL | AUT | AUS | 4 |
NCT01800695 | Phase I | Temozolomide Depatuxizumab mafodotin | Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme | Completed | 0 | |
NCT01741727 | Phase II | Depatuxizumab mafodotin | A Study of ABT-414 in Subjects With Solid Tumors | Completed | USA | CAN | 0 |